Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 2.4 | 1.36 |
NAV | ₹9.78 | ₹203.53 |
Fund Started | 31 Jul 2025 | 07 May 2007 |
Fund Size | ₹691.38 Cr | ₹89383.23 Cr |
Exit Load | Exit load of 1%, if redeemed within 60 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | - | 5.94% |
3 Year | - | 24.58% |
5 Year | - | 26.08% |
1 Year
3 Year
5 Year
Equity | 95.77% | 93.94% |
Cash | 4.23% | 6.06% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Bharti Hexacom Ltd. | 4.52% |
Multi Commodity Exchange Of India Ltd. | 4.04% |
ICICI Bank Ltd. | 3.99% |
Indian Bank | 3.91% |
Hero Motocorp Ltd. | 3.77% |
Abbott India Ltd. | 3.36% |
Jindal Stainless Ltd. | 3.27% |
UNO Minda Ltd. | 3.00% |
CreditAccess Grameen Ltd. | 2.95% |
Bharat Dynamics Ltd. | 2.88% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.46% |
AU Small Finance Bank Ltd. | 3.70% |
Indian Bank | 3.54% |
The Federal Bank Ltd. | 3.38% |
Balkrishna Industries Ltd. | 3.37% |
Fortis Healthcare Ltd. | 3.19% |
Coforge Ltd. | 3.11% |
Hindustan Petroleum Corporation Ltd. | 2.96% |
Glenmark Pharmaceuticals Ltd. | 2.67% |
Ipca Laboratories Ltd. | 2.52% |
Name | Alok Singh | Chirag Setalvad |
Start Date | 31 Jul 2025 | 28 Jun 2014 |
Name
Start Date
Description | The scheme is to generate long-term capital appreciation by investing predominantly in equity and equity related instruments of mid cap companies. However, there is no assurance that the investment objective of the Scheme will be achieved. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 31 Jul 2025 | 07 May 2007 |
Description
Launch Date